Literature DB >> 22379256

Six-minute walk test for persons with mild or moderate disability from multiple sclerosis: performance and explanatory factors.

Jane L Wetzel1, Donna K Fry, Lucinda A Pfalzer.   

Abstract

PURPOSE: The primary purpose of this study was to determine the extent to which health factors, functional measures, and pulmonary impairment explain performance on 6-Minute Walk Test (6MWT) distance in ambulatory persons with multiple sclerosis (MS). Another purpose was to determine the effect of disability and age on 6MWT performance and explanatory factors.
METHODS: A cross-sectional study design was used to evaluate factors that explain performance on the 6MWT in 64 community-dwelling persons with MS-related disability (Expanded Disability Status Scale [EDSS] 3.8±1.6). Of the 64 participants, 43 (67.2%) exhibited mild disability (EDSS <4.0) and 21 (32.8%) had moderate disability (EDSS 4.0-6.5). A regression analysis compared 6MWT performance to measures of health factors (EDSS, number of medications, number of comorbidities, resting HR, systolic and diastolic blood pressure [BP]); physical performance (functional stair test [FST], sit-to-stand test [SST], static standing balance [BAL], Fatigue Severity Scale [FSS], Activities-specific Balance Confidence [ABC] Scale); and pulmonary function (forced expiratory volume in 1 second [FEV(1)], forced vital capacity [FVC], maximal voluntary ventilation [MVV], maximal inspiratory pressure [MIP], maximal expiratory pressure [MEP]).
RESULTS: EDSS, ABC, FST, SST, BAL, MVV, MIP, and MEP were significantly associated with 6MWT distance after adjusting for age. Multiple step-wise linear regression analysis revealed that ABC, FST, and BAL were significant and independent explanatory factors of 6MWT distance. ABC and FST explained 75% of the variance in 6MWT performance (R(2)=0.75). Curvilinear regression analysis revealed that the FST is the most significant explanatory factor for 6MWT distance, explaining 79% of the variance (R(2)=0.79).
CONCLUSIONS: 6MWT performance in persons with MS was explained by balance confidence (ABC) and stair-climbing ability (FST). The ABC and FST may be practical clinical measures for explaining walking ability and determining risk for disablement in persons with MS.

Entities:  

Keywords:  6MWT; fatigue; multiple sclerosis; muscle strength; postural balance; walking

Mesh:

Year:  2011        PMID: 22379256      PMCID: PMC3076913          DOI: 10.3138/ptc.2009-62

Source DB:  PubMed          Journal:  Physiother Can        ISSN: 0300-0508            Impact factor:   1.037


  60 in total

1.  Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery.

Authors:  J M Guralnik; L Ferrucci; C F Pieper; S G Leveille; K S Markides; G V Ostir; S Studenski; L F Berkman; R B Wallace
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2000-04       Impact factor: 6.053

2.  Lower extremity performance in nondisabled older persons as a predictor of subsequent hospitalization.

Authors:  B W Penninx; L Ferrucci; S G Leveille; T Rantanen; M Pahor; J M Guralnik
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2000-11       Impact factor: 6.053

3.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

4.  Reference values for a multiple repetition 6-minute walk test in healthy adults older than 20 years.

Authors:  W J Gibbons; N Fruchter; S Sloan; R D Levy
Journal:  J Cardiopulm Rehabil       Date:  2001 Mar-Apr       Impact factor: 2.081

5.  The Activities-specific Balance Confidence (ABC) Scale.

Authors:  L E Powell; A M Myers
Journal:  J Gerontol A Biol Sci Med Sci       Date:  1995-01       Impact factor: 6.053

6.  Age-related disability in multiple sclerosis.

Authors:  Maria Trojano; Maria Liguori; Giovanni Bosco Zimatore; Roberto Bugarini; Carlo Avolio; Damiano Paolicelli; Fabrizio Giuliani; Francesca De Robertis; Maria Giovanna Marrosu; Paolo Livrea
Journal:  Ann Neurol       Date:  2002-04       Impact factor: 10.422

7.  The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus.

Authors:  L B Krupp; N G LaRocca; J Muir-Nash; A D Steinberg
Journal:  Arch Neurol       Date:  1989-10

8.  Functional walk tests in individuals with stroke: relation to perceived exertion and myocardial exertion.

Authors:  Janice J Eng; Kelly S Chu; Andrew S Dawson; C Maria Kim; Katherine E Hepburn
Journal:  Stroke       Date:  2002-03       Impact factor: 7.914

9.  Shared risk factors for falls, incontinence, and functional dependence. Unifying the approach to geriatric syndromes.

Authors:  M E Tinetti; S K Inouye; T M Gill; J T Doucette
Journal:  JAMA       Date:  1995-05-03       Impact factor: 56.272

10.  Environmental demands associated with community mobility in older adults with and without mobility disabilities.

Authors:  Anne Shumway-Cook; Aftab E Patla; Anita Stewart; Luigi Ferrucci; Marcia A Ciol; Jack M Guralnik
Journal:  Phys Ther       Date:  2002-07
View more
  17 in total

1.  Clinician's Commentary.

Authors:  Kathryn M Sibley
Journal:  Physiother Can       Date:  2011-04-13       Impact factor: 1.037

2.  Motor unit discharge characteristics and walking performance of individuals with multiple sclerosis.

Authors:  Awad M Almuklass; Leah Davis; Landon D Hamilton; Taian M Vieira; Alberto Botter; Roger M Enoka
Journal:  J Neurophysiol       Date:  2018-01-03       Impact factor: 2.714

3.  Changes in trunk and head acceleration during the 6-minute walk test and its relation to falls risk for adults with multiple sclerosis.

Authors:  Steven Morrison; C Armitano-Lago; C A Rynders; J J Sosnoff
Journal:  Exp Brain Res       Date:  2022-01-28       Impact factor: 1.972

4.  Efficacy of Transcranial Direct Current Stimulation (tDCS) on Balance and Gait in Multiple Sclerosis Patients: A Machine Learning Approach.

Authors:  Nicola Marotta; Alessandro de Sire; Cinzia Marinaro; Lucrezia Moggio; Maria Teresa Inzitari; Ilaria Russo; Anna Tasselli; Teresa Paolucci; Paola Valentino; Antonio Ammendolia
Journal:  J Clin Med       Date:  2022-06-17       Impact factor: 4.964

5.  The optimal cutoff score of the 2-min step test and its association with physical fitness in type 2 diabetes mellitus.

Authors:  Arunrat Srithawong; Puttipong Poncumhak; Pacharee Manoy; Sirintip Kumfu; Tichanon Promsrisuk; Piyapong Prasertsri; Orachorn Boonla
Journal:  J Exerc Rehabil       Date:  2022-06-27

6.  Randomized controlled trial of physical activity, cognition, and walking in multiple sclerosis.

Authors:  Brian M Sandroff; Rachel E Klaren; Lara A Pilutti; Deirdre Dlugonski; Ralph H B Benedict; Robert W Motl
Journal:  J Neurol       Date:  2013-12-10       Impact factor: 4.849

7.  Two-minute versus 6-minute walk distances during 6-minute walk test in neuromuscular disease: Is the 2-minute walk test an effective alternative to a 6-minute walk test?

Authors:  J W Witherspoon; R Vasavada; R H Logaraj; M Waite; J Collins; C Shieh; K Meilleur; C Bönnemann; M Jain
Journal:  Eur J Paediatr Neurol       Date:  2018-10-23       Impact factor: 3.140

8.  Effects of Treadmill Training on Muscle Oxidative Capacity and Endurance in People with Multiple Sclerosis with Significant Walking Limitations.

Authors:  T Bradley Willingham; Jonathan Melbourn; Marina Moldavskiy; Kevin K McCully; Deborah Backus
Journal:  Int J MS Care       Date:  2019 Jul-Aug

9.  Case Report: Effect of Antigravity Treadmill Training on Muscle Oxidative Capacity, Muscle Endurance, and Walking Function in a Person with Multiple Sclerosis.

Authors:  T Bradley Willingham; Jonathan Melbourn; Marina Moldavskiy; Kevin K McCully; Deborah Backus
Journal:  Int J MS Care       Date:  2018 Jul-Aug

10.  An exploration of impaired walking dynamics and fatigue in multiple sclerosis.

Authors:  Janina M Burschka; Philipp M Keune; Uwe Menge; Ulrich Hofstadt-van Oy; Patrick Oschmann; Olaf Hoos
Journal:  BMC Neurol       Date:  2012-12-27       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.